logo
Plus   Neg
Share
Email

Oncolytics Meets Primary Endpoint For First Stage Of Phase 2 Lung Cancer Trial

Oncolytics Biotech Inc. (ONC.TO, ONCY) reported preliminary results from its U.S. Phase 2 trial in patients with squamous cell carcinoma of the lung or SCCLC using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel. The Principal Investigator is Alain Mita of Cedars-Sinai Medical Centre in Los Angeles, CA.

The study's primary objective is to assess the antitumor effect of the treatment regimen in the study population in terms of objective response rates, while the secondary objectives are to assess progression-free survival and overall survival for the treatment regimen in the study population; to determine the proportion of patients receiving the above treatment who are alive and free of disease progression at six months; and to assess the safety and tolerability of the treatment regimen in the study population.

The study is a two stage design, wherein up to 19 evaluable patients with SCCLC were to be treated in the first stage. If four or more patients demonstrated a partial response or better, the study would then proceed to the second stage, with up to 55 patients being treated in the entire study. This endpoint was met after 15 evaluable patients were enrolled. According to the company, five of 15 patients showed partial response, four confirmed, one unconfirmed, and an additional eight patients had stable disease, for 87% disease control rate.

The company said it is proceeding with the second stage of the study.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT